Introduction
============

The neuronal network is established precisely during development for normal functioning of the neuronal system. To form synaptic connections, a neuron sends out an axon, projecting toward a distant target, and several dendrites to receive signals from the axon terminals of upstream neurons. Throughout the trajectory toward the target growth cone, a specialized structure at the tip of the extending axon is controlled by attractive and repulsive cues in its surroundings, called axon guidance molecules. Neuronal guidance molecules include semaphorins, netrins, ephrins, and Slit, and their corresponding receptors include neuropilins, UNC5, or DCC families, Eph, and roundabouts (Robo). However, it has been shown that axon guidance molecules also have non-neuronal functions, particularly in the development of the immune ([@B32]) and vascular systems ([@B9]; [@B30]). Moreover, these ligands and receptors have pivotal roles in tumor progression, especially in tumor growth and metastasis ([@B46]; [@B41]). In this review, we will summarize our knowledge of the biological and molecular mechanisms of axon guidance, specifically semaphorins and netrins, focussing on signal transduction in various cell types, tumor cells, ECs, and immune cells. The goal of this article is to describe the evidence that links axon guidance molecules as regulators of the tumor microenvironment.

Semaphorins and Their Receptors
-------------------------------

The semaphorins were first described as repulsive cues of axon pathfindings during neuronal development ([@B38]). In vertebrates, more than 20 members of the semaphoring family have been identified and characterized into five classes (semaphorin 3--7) based on structural properties; class 3 semaphorins (SEMA3s) are secreted proteins, class 4--6 semaphorins are transmembrane proteins, and semaphorin 7A is a membrane-associated protein ([@B46]). Most semaphorins elicit signals into the cells by plexins, a family of nine transmembrane receptors. The plexins are subdivided into four subfamilies: plexin A1-A4, plexin B1-B3, plexin C1 and plexin D1. The cytoplasmic region of plexins contains a split GTPase-activating protein (GAP) domain that binds directly to small intracellular GTPase. Neuropilins are also key receptors of semaphorins, especially SEMA3s. There are two genes, NRP1 and NRP2, with approximately 50% structural homology and functional domain structure. The extracellular domain is divided into three subdomains. The a1a2 and b1b2 are ligand-binding domains, while the c domain is crucial for dimerization, to form NRP homo- and heterodimerization ([@B21]; [@B11]). SEMA3s bind to NRP1 or NRP2 receptors, subsequently forming complexes with the plexin A family and transduce signals into the cells. However, SEMA3E is an exception because it directly binds to plexin D1 without NRPs ([@B31]).

### Endothelial Cell

Over the last two decades, it has been clear that the interaction of semaphorins and their receptors, regulates many processes beyond axon guidance, including angiogenesis and immune responses ([@B30]; [@B32]). For example, NRP1 was originally found as a receptor of semaphorin III/D, also known as collapsin-1 or semaphorin 3A (SEMA3A), and contributed to accurate axon pathfinding ([@B21]). NRP1 is also expressed on ECs. NRP1 acts as a co-receptor to enhance binding of the vascular endothelial growth factor 165 (VEGF165), but not VEGF121, to VEGF receptor-2 (VEGFR2), thereby inducing chemotactic and mitogenic activity ([@B67]). Conversely, SEMA3A binding to NRP1 inhibits EC migration. VEGF165 and SEMA3A compete with each other in EC migration, collapsing activity, and NRP1 binding ([@B43]), therefore, SEMA3A inhibits angiogenesis.

The plexin family receptors also play an important role in regulating angiogenesis. For example, plexin D1, a receptor of SEMA3E, is highly expressed on ECs during development ([@B71]). Interestingly, plexin D1 expression is induced by VEGF in tip cell at the vascular front. The interaction of SEMA3E and plexin D1 negatively regulates the VEGF-induced delta-like 4-Notch singling pathway, which controls cell fate decisions between tip and stalk cells ([@B29]). Moreover, in zebrafish models, SEMA3-plexin D1 signaling restricts angiogenic activity by the proper endothelial abundance of soluble flt1, an alternatively spliced form of the VEGF receptor Flt1 as a powerful secreted decoy protein ([@B84]).

### Immune Cell

The role of semaphorins and their receptors in the immune system has become clear in recent years ([@B32]). NRP1 is highly expressed on Foxp3+ CD4+ T helper cells called regulatory T (Treg) cells. Several groups have shown that NRP1 is useful to distinguish thymus-derived naturally occurring Tregs (nTregs) from peripherally generated adaptive Treg (iTreg) cells ([@B73]; [@B78]). The lack of NRP1 on CD4+ T cells result in enhanced immune responses in experimental autoimmune encephalitis (EAE). NRP1-deficient CD4+ T cells display an increased Th-17 phenotype, enhanced proliferation and cytokine production, and impairs Treg cell function ([@B68]).

Among the plexin family members, plexin-A1 has been implicated in dendritic cell (DC) function in the immune system. Plexin A1 is highly expressed in mature DCs. Indeed, plexin A1 expression is induced by the MHC class II transactivator (CIITA) ([@B75]). Plexin A1-deficient mice impair the generation of antigen-specific T cells, indicating that plexin A1 is required for DC-mediated T cell responses. In addition, SEMA3A produced by lymphatic EC regulates DC migration and trafficking from peripheral tissues, draining lymph nodes. SEMA3A-plexin A1 interaction induces cytoskeletal fiber rearrangement and DC morphological changes, which allows cells to pass through narrow gaps. Interestingly, depletion of plexin A1 in mice, result in abnormalities not only in immune responses but also in bone homeostasis. Plexin A1 forms a complex with the triggering receptor expressed on myeloid cells 2 (TREM2) and the adaptor molecule DNAX-activation protein 12 (DAP12) on osteoclasts. This complex mediates osteoclast differentiation through PLCγ signaling ([@B70]). These findings show that plexin A1 is indispensable in both immune and skeletal systems ([@B70]; [@B32]).

### Tumor Cell

The semaphorins are also involved in pathological situations such as tumor progression ([@B8]; [@B56]) and tumor immunity ([@B32]). For example, semaphorin 3B (SEMA3B) and 3F (SEMA3F) were initially identified as tumor suppressors in lung cancer, because small cell lung cancer is correlated with a deletion in the short arm of chromosome 3 (3p21) ([@B58]; [@B77]). In addition, SEMA3F expression is downregulated by ZEB-1, an E-box transcription repressor in lung cancer. ZEB-1 directly binds to the promoter region of the SEMA3F gene and suppresses SEMA3F transcription ([@B12]). Moreover, SEMA3F and its receptor NRP2 are direct target genes of the tumor suppressor p53, indicating that the SEMA3F-NRP2 signaling is involved in a tumor suppressive pathway ([@B18]).

The expression of SEMA3F is consistently downregulated in highly metastatic tumor cells including the prostate, bladder, and melanoma cells *in vitro* and *in vivo* ([@B5]). Conversely, tumor cells expressing SEMA3F, inhibit cell adhesion, migration *in vitro*, and tumor angiogenesis and metastasis *in vivo* ([@B5]; [@B27]). More recently, we reported that SEMA3E and SEMA3F are powerful inhibitors of proliferation, migration, and the sprouting of infantile hemangioma cells ([@B45]).

Overall, semaphorins are characterized as multiple functional regulators in several physiological and pathological events. Nevertheless, the molecular mechanisms of semaphorin activity in diverse cell types are poorly understood. Here, we will review our recent data with a focus on the intracellular signaling mechanisms of semaphorin 3F (SEMA3F) in tumors and ECs.

Regulation of Actin Cytoskeleton by SEMA3F
------------------------------------------

The majority of research on axon guidance signaling pathways has focused on neuronal cells, especially in the rearmament of the cytoskeleton and plasma membrane in growth cones and axons ([@B24]). SEMA3A/collapsin-1 was first identified as a repulsive cue that collapses growth cones and repels axons in dorsal root ganglia (DRG) ([@B38]). Soon after, Klagsbrun and co-workers found that NRP1 is expressed on ECs ([@B67]) and that SEMA3A inhibits the micro vessel outgrowth from rat aortic rings ([@B43]). Similarly, SEMA3A collapses the endothelial tip cell, the leading edge of capillaries, and retracts lamellipodia structures in ECs.

Subsequent studies by the Klagsbrun lab demonstrated that a small GTPase RhoA plays a key role in mediating SEMA3s-induced collapsing activity in tumor cells and ECs ([@B65]; [@B53]). Through phalloidin staining, both SEMA3A and SEMA3F significantly reduce the number of stress fibers in U87MG glioblastoma cells and the human umbilical vein EC (HUVEC). Initially, SEMA3F forms a complex between NRP2 and plexin A1 and recruits ABL2, a membrane-anchored non-receptor tyrosine kinase, and subsequently phosphorylates p190RhoGAP. Activated p190RhoGAP inactivates RhoA, converting GTP to GDP, which phosphorylates cofilin, an actin depolymerizing factor. As a result, active cofilin depolymerizes F-actin, leading to cytoskeletal collapse (Figure [1](#F1){ref-type="fig"}) ([@B65]). This signaling pathway mediated by SEMA3A and 3F is blocked by Gleevec (imatinib, STI571), an the ABL2 tyrosine kinase inhibitor. Gleevec administration protects tumors and ECs from a SEMA3s-induced cytoskeletal collapse and loss of migration ([@B53]).

![SEMA3F signaling pathways (adapted from [@B65]; [@B44]). SEMA3F binds to NRP2 and forms a complex with Plexin A1, inactivating PI-3K and mTORC2/Akt-dependent signaling in various cell types. Functionally, these regulatory/pro-resolution signals suppress cell proliferation, migration, cytoskeletal stress fiber rearrangement, and cell survival. SEMA3F also inhibits the cytoskeleton structure in part, by inactivating RhoA through both the ABL2 kinase and p190RhoGAP.](fphys-09-01662-g001){#F1}

SEMA3F as a Novel mTOR Inhibitor
--------------------------------

We profiled levels of phosphokinases in NRP2-expressing tumor cells to determine the inhibitory effect of SEMA3F. In glioblastoma cells, SEMA3F inhibits the phosphorylation of Akt (T308 and S473), Erk, mTOR, and S6K, the mTOR downstream molecule, via NRP2 and plexin A1 receptors ([@B44]). SEMA3F also inhibits Akt-mTOR signaling in several other cell lines expressing NRP2, including lung cancer cells, melanocytes, Jurkat T lymphocytes, and ECs ([@B52]; [@B44]). Moreover, PI-3K, a regulator of Akt, is also deactivated by SEMA3F in tumor and ECs, suggesting that SEMA3F is a powerfull inhibitor of the PI-3K-Akt-mTOR signaling pathway (Figure [1](#F1){ref-type="fig"}).

mTOR is a serine/threonine kinase that exists as two distinct multiprotein complexes, composed of either mTOR, raptor, and mLST8 (mTORC1) ([@B28]; [@B60]) or mTOR, rictor, Sin1, protor, and mLST8 (mTORC2) ([@B61]; [@B79]; [@B51]). mTORC1 and mTORC2 signaling is critical for cell metabolism, differentiation, proliferation, and survival of many normal cell types. Through immunoprecipitation, we found that SEMA3F inhibits the association between mTOR, raptor and rictor in glioblastoma cells, suggesting an inhibitory effect on both mTORC1 and mTORC2, respectively. A recent study showed that invertebrate semaphorin-plexin interactions regulate TOR signaling in *Caenorhabditis elegans* (*C. elegans*), which is required for morphological changes in its epidermal cells ([@B47]). Rapamycin, an inhibitor of mTOR, markedly inhibits S6K phosphorylation, but induces Akt phosphorylation by blocking the negative feedback loop via mTORC1/S6K ([@B83]; [@B14], [@B13]). Importantly, SEMA3F inhibits both S6K and rapamycin-induced Akt activation when cells were treated with rapamycin and subsequently treated with SEMA3F. This SEMA3F inhibitory effect on Akt-mTOR signaling is similar to that observed in cells treated with the mTORC1/C2 inhibitor Torin 1. SEMA3F also inhibits other known targets of mTORC2, serum/glucocorticoid-regulated kinase-1 (SGK1) and protein kinase C (PKCα), indicating that SEMA3F is a powerful inactivator of mTORC2 (Figure [1](#F1){ref-type="fig"}) ([@B44]).

As we previously reported ([@B65]), SEMA3F-NRP2 interactions result in the cytoskeletal collapse in tumor cells and ECs via the RhoA pathway. Since mTORC2 is reported to mediate F-actin cytoskeleton re-organization by interacting with the Rho GTPase family ([@B61]; [@B25]), we tested whether the inhibition of mTORC2 alters F-actin formation in tumor cells. We found that treatment with Torin 1 inhibits the stress fibers in the cells, whereas the mTORC1 inhibitor rapamycin fails to elicit any cytoskeletal changes. Knockdown of rictor (mTORC2) by its specific siRNA, but not raptor (mTORC1), attenuates RhoA activity. Collectively, SEMA3F inactivates RhoA in part via mTORC2 and in part via another mechanism such as the ABL2/p190RhoGAP pathway (Figure [1](#F1){ref-type="fig"}) ([@B65]; [@B44]).

We further analyzed the effect of SEMA3F on the regulation of VEGF, a key mediator of angiogenesis. SEMA3F inhibits VEGF promoter activity and secretion induced by the treatment with a hypoxia mimetic agent desferrioxamine (DFO) or hypoxia (1% O~2~) in glioblastoma cells. On the other hand, SEMA3F fails to attenuate VEGF promoter activity in 2DAkt (constitutively active Akt) transfected cells following treatment with DFO ([@B44]). In lung cancer cells, consistent with our results, SEMA3F downregulates the hypoxia-inducible factor-1α (HIF-1α) protein and VEGF mRNA levels by blocking the Akt-mTOR signaling pathway ([@B52]). These findings indicate that SEMA3F suppresses the angiogenic property of tumor cells by inhibiting the production and secretion of VEGF and interrupting VEGF-NRP binding.

There is great interest in targeting mTOR signaling pathways as a therapeutic approach for several diseases such as autoimmune disease, chronic inflammation and allograft rejection, and as an adjunct to cancer therapy ([@B62]). However, many mTOR inhibitors have potential side effects such as immunosuppression and glucose intolerance. Because SEMA3F suppresses rapamycin-induced Akt activation, the combination of SEMA3F with mTOR inhibitors may provide a clinical benefit in cancer therapy.

Therapeutic Potential of SEMA3F
-------------------------------

Several groups, including ours, have demonstrated that SEMA3F inhibits tumor growth, angiogenesis and metastasis in various tumors, such as melanoma ([@B5]), osteosarcoma ([@B35]), ovarian cancer ([@B23]), colon cancer ([@B76]; [@B55]), and lung cancer ([@B52]). The effect of SEMA3F on tumor progression has been examined in a well-established xenograft model: parental tumor cells or cells that are engineered to overexpress SEMA3F are implanted into nude mice. For example, high metastatic melanoma cells were transfected with SEMA3F and implanted into mice skin. As a result, the ensuing SEMA3F-tumor did not metastasize into the lymph nodes or lungs. The primary tumors expressing SEMA3F displayed large areas of apoptosis and diminished vascularity ([@B5]). Similarly, tumor growth was essentially absent when SEMA3F-producing glioblastoma cells were implanted into mice skin compared to parental cells. Additionally, CD31-positive capillaries within the SEMA3F-tumor were constricted and had no discernable lumens ([@B44]).

In another approach using an *in vivo* model, we injected glioblastoma cells into the skin of nude mice, and after 2 days, the mice received a single intravenous injection of adenovirus encoding human SEMA3F (Ad-3F) or a control adenovirus (Ad-Cont) ([@B44]). Tumor growth was inhibited over a 14-day period in mice injected with Ad-3F, compared to Ad-Cont-treated. There was a collapsed phenotype of CD31-positive capillaries within tumors in Ad-3F-treated mice. Moreover, through western blot analysis, it was observed that Akt-mTOR signaling was suppressed in tumors of the Ad-3F mice, compared to the control group. In this model, SEMA3F levels were measurable by ELISA or western blot in the serum and the liver, respectively. These results indicate that SEMA3F administration, either local or systemic, has similar anti-tumor and anti-angiogenic effects, by inhibiting the Akt-mTOR singling pathway ([@B44]).

A recent study showed that a rationally designed SEMA3A mutant, that elicits NRP1-independent signals via the plexin A4 receptor, is an effective anti-tumor agent. Mutant SEMA3A successfully normalized the vasculature, inhibited tumor growth, metastasis, and improved efficacy of chemotherapy in pancreatic cancer mouse models ([@B19]). Based on this study, mutant SEMA3F may also have a similar potential. Moreover, furin-mediated processing of the C-terminal of SEMA3s (SEMA3-95kD) is required as an anti-angiogenic factor, whereas processing in the semaphorin domain (SEMA3-65kD) results in the reduction of repulsive activity ([@B1]; [@B50]). These results suggest that the resistant form of the furin protease, SEMA3F-95kD, may be more effective and stable *in vivo*.

It has been reported that NRP1 mediates the infiltration of the Foxp3+ Treg cell into the tumor and regulates the immunological anti-tumor control in response to tumor-derived VEGF ([@B20]). The T cell-specific knockout of NRP1 blocks tumor infiltration of Tregs and restores the anti-tumor effect, eventually inhibiting tumor growth. Since SEMA3s compete with VEGF for NRP binding, treatment with SEMA3s may enhance anti-tumor activity by impairing Treg infiltration induced by VEGF. However, the functions of NRP2 in immune systems are poorly understood ([@B59]; [@B63]). Further studies are needed to identify the effect of SEMA3F as an immune modulator.

Overall, SEMA3F is a secreted physiological mTOR inhibitor that functions to inhibit tumor growth, angiogenesis, and metastasis. SEMA3F has therapeutic potential, not only in tumor biology, but also to target immune-related diseases such as allograft rejection.

Netrins and Their Receptors
---------------------------

Netrins are laminin-like proteins first identified as axonal guidance cues, guiding axons during the neural development of *C. elegans* ([@B22]). In vertebrates, the netrin family consists of secreted axon guidance molecules that include netrin-1, netrin-3 (also known as netrin-2 chicken-like), and netrin-4. Two other netrins, netrin-G1 and netrin-G2, are characterized by glycosylphosphatidylinositol (GPI) anchorage to the cells. The floor plate-secreted netrin-1 diffuses and establishes a gradient to attract commissural axons expressing netrin receptors to the midline of the central nervous system during the development. Netrin family activity is mediated by several receptors, including uncoordinated 5A-D (UNC5A-D), deleted in colorectal cancer (DCC), its ortholog neogenin, and the Down syndrome cell adhesion molecule (DSCAM). Netrin receptors, called dependence receptors, play a dual role in regulating multiple cellular responses: they mediate positive signals, such as promoting cell proliferation, migration, and survival, in the presence of netrin-1 ligand, while netrin receptors trigger apoptosis under netrin-1 ligand limited conditions ([@B36]).

### Tumor Cell

Netrin-1 also has a number of non-neuronal functions: regulating angiogenesis ([@B37]; [@B49]; [@B74]; [@B33]), inflammation ([@B69]; [@B6]), and tumor progression ([@B41]). For example, the netrin-1 receptor DCC was identified originally as a tumor suppressor in colon cancer associated with a deletion in chromosome 18q21 ([@B16]). Loss of netrin-1 receptor expression or inactivation of these receptors are associated with a poor prognosis in patients with colorectal tumors, glioblastoma, and breast carcinoma ([@B57]; [@B4]). On the other hand, upregulation of netrin-1 is observed in some types of cancers. Recently, netrin-1 has been identified as a stimulator of tumor progression in breast cancer ([@B17]), colorectal cancer ([@B48]), gastric cancer ([@B80]), and medulloblastoma ([@B2]).

### Endothelial Cell

However, in the vascular system, it is still controversial whether netrin-1 is a promoter or an inhibitor of angiogenesis. For example, netrin-1 induces proliferation and migration of EC in wound healing ([@B49]). Additionally, netrins accelerated neovascularization and reversed neuropathy and vasculopathy in murine models of ischemia ([@B74]). Conversely, activation of UNC5B receptor by netrin-1 mediates repulsive cues for EC sprouting ([@B33]). Disruption of Unc5B in mice or zebrafish increased vessel branching and abnormal navigation, suggesting a negative role for netrin-1 in vasculogenesis ([@B37]; [@B33]). These inconsistent results might be explained by the bifunctional nature of netrin receptors, which mediate attraction or repulsion, dependent on differential netrin receptor expression levels.

### Immune Cell

Netrin-1 is also described as a mediator of the immune response. Netrin-1 is expressed in the vascular endothelium; however, its expression is downregulated during infection *in vivo* ([@B39]). Netrin-1 receptor UNC5B is expressed in leucocytes, netrin-1 acts as a potent inhibitor of the migration of leukocytes *in vitro* and *in vivo* ([@B39]). Recently, we examined the expression of netrin receptors on human CD4+ T cells. We found that neogenin, UNC5A and UNC5B are expressed by CD4+ T cells at low levels in the steady state; however, protein levels of these receptors are induced following mitogenic activation ([@B6]). Using a microfluidic assay ([@B7]), we found that netrin-1 stimulates bidirectional migration of mitogen-activated CD4+ T cells. Knockdown of neogenin by shRNA attenuates netrin-1-induced migratory activity of CD4+ T cells, indicating that netrin-1 mediates promigratory signals via the neogenin receptor. As mentioned above, the biology of netrin-1 is complex because of its potential to interact with attractive or repulsive receptors. In addition, the effects of netrins are even more complex when considering that there are 3 members of the netrin family: netrin-1, netrin-3, and netrin-4. For example, netrin-4 inhibits angiogenesis via neogenin and UNC5B ([@B34]) and suppresses tumor angiogenesis in colorectal cancer ([@B15]).

In a humanized SCID mouse model, local injection of netrin-1 into the skin, enhanced immigration of neogenin-expressing CD3+ T cell. Additionally, neogenin is expressed on CD3+ T cell infiltrates within human cardiac allograft biopsies, with evidence of rejection. These results suggest that netrin-1/neogenin interactions augment the T cell chemokinetic response in the process of T cell immigration into human allografts ([@B6]).

Other evidence shows that netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques via the UNC5B receptor ([@B72]). Conversely, targeted deletion of netrin-1 in macrophages, attenuates atherosclerosis in mouse models. Moreover, netrin-1 is highly expressed in adipose tissue in obese mice and promotes macrophage retention via UNC5B, and eventually enhances chronic inflammation and insulin resistance ([@B54]).

Overall, netrin-1 plays a crucial role in regulating acute/chronic inflammation, angiogenesis, and tumor and EC invasiveness. Here, we will discuss the molecular mechanisms of how netrin and its receptors regulate multiple cellular functions, in particular, in tumor cells and ECs.

Regulation of Actin Cytoskeleton by Netrin-1
--------------------------------------------

Glioblastomas are highly invasive brain tumors. Netrin-1 promotes glioblastoma cell migration and invasion by Transwell coated with gelatin (migration) or Matrigel (invasion) assays. In *in vivo* xenograft models, glioblastoma cells overexpressing netrin-1, display metastatic lesions in lymph nodes after 1-month post-resection of primary tumors implanted subcutaneously on the dorsal flank of nude mice. These results show that netrin-1 stimulates glioblastoma cell invasiveness *in vitro* and *in vivo* ([@B66]). Mechanistically, netrin-1 induces glioblastoma cell stress fiber formation by activating the RhoA and cofilin pathway. This netrin-1 effect is the inverse to that of SEMA3F as mentioned above, which inactivates RhoA, thereby collapsing F-actin cytoskeleton.

Netrin-1 also stimulates EC invasion, sprouting, and tube formation ([@B66]; [@B2]). Consistent with the results of glioblastoma cells, netrin-1 induces EC stress fiber formation and invasion via a RhoA and cofilin pathway. The neogenin receptor is highly expressed in mouse brain capillary EC. Knockdown of neogenin by siRNA in EC significantly decreases netrin-1-induced EC invasion and tube formation. Moreover, netrin-1 induces CD31-positive EC infiltration into Matrigel, which is abrogated by the neogenin neutralizing antibody.

Netrin-1 Activates Cathepsin B and CREB
---------------------------------------

Alternatively, netrin-1-induced cell invasion is mediated by activated cathepsin B (CatB), a cysteine protease that translocates to the cell surface as an active enzyme. The netrin-1-induced translocation of CatB to the cell surface was abrogated by a RhoA inhibitor C3 transferase, indicating that netrin-1-induced CatB activation and translocation were dependent on RhoA activation. The CatB specific inhibitor, CA-074Me, inhibits netrin-1-induced cell invasion. We further investigated the intracellular signaling pathways mediated by netrin-1 with a phosphoprotein antibody array. Netrin-1 induces phosphorylation of the ERK and CREB (cAMP-response element-binding protein) in glioblastoma cells. CREB is a transcription factor involved in the cell invasion and metastasis of tumors ([@B42]; [@B64]). Knockdown of the CREB reduces glioblastoma cell invasiveness, sprouting and CatB expression. Taken together, netrin-1 activates glioblastoma cell invasion in a RhoA-, CREB-, and CatB-dependent manner (Figure [2](#F2){ref-type="fig"}) ([@B66]).

![Netrin-1 signaling pathways (adapted from [@B66]). Netrin-1 activates RhoA in glioblastoma cells and ECs, enhancing stress fiber formation and compromising the integrity of the F-actin cytoskeleton. Netrin-1 also induces the phosphorylation of CREB via the MAPK pathway, leading to up-regulation of CatB expression. Netrin-1 promotes the translocation of CatB from the lysosome to the cell surface as an enzymatically active form in a RhoA-dependent manner. Once at the cell surface, CatB acts to promote glioblastoma invasiveness and angiogenesis.](fphys-09-01662-g002){#F2}

Netrin-1 as a Biomarker of Medulloblastoma
------------------------------------------

Medulloblastoma is the most common malignant pediatric brain tumor. For patients with invasive or disseminated medulloblastoma, the 5-year survival rate can be as low as 32% ([@B82]). The mechanisms underlying the invasion and dissemination in medulloblastoma still remain elusive. Based on the results that netrin-1 induces glioblastoma cell invasion ([@B66]), we tested the netrin-1 effect on medulloblastoma. We showed that netrin-1 stimulated medulloblastoma cell invasion via neogenin and UNC5B receptors. Inhibition of netrin-1 by the neutralizing antibody, blocked medulloblastoma cell invasion and reduced phosphorylation of the ERK and CatB expression. Moreover, the MEK inhibitor U0126, reduced CatB expression in medulloblastoma. These inhibition results suggest that netrin-1 secreted by medulloblastoma cells, stimulates medulloblastoma cell invasiveness by activating the CatB via the MAPK pathway ([@B2]).

In pediatric medulloblastoma patients, netrin-1 mRNA and protein levels are elevated in medulloblastoma specimens compared with control specimens from the same patient. Urinary netrin-1 levels are also higher in medulloblastoma patients compared with controls. Importantly, urinary netrin-1 is higher in patients with invasive medulloblastoma compared with non-invasive medulloblastoma. Notably, urinary netrin-1 levels diminished after the resection of medulloblastoma in patients. These results suggest that the netrin-1-neogenin (or UNC5B) pathway is a promising therapeutic target to inhibit medulloblastoma invasiveness, and that the measurement of netrin-1 might be useful to detect invasive and disseminated phenotypes of medulloblastoma to predict the disease status ([@B2]).

Conclusion and Future Perspectives
==================================

An increasing body of data indicates that axon guidance molecules are crucial regulators of the tumor microenvironment. We have summarized the current evidence that SEMA3F and netrin-1 have multifaceted effects on tumors and surrounding non-tumor cells, including ECs, leukocytes, macrophages, and fibroblasts (Figure [3](#F3){ref-type="fig"}). Therefore, we propose that targeting SEMA3F and netrin-1 may be a promising strategy for cancer therapy.

![Axon guidance molecules are crucial regulators of the tumor microenvironment. SEMA3F and netrin-1 have multifaceted effects on tumors and surrounding non-tumor cells, including ECs, leukocytes, macrophages, and fibroblasts etc. Treatment with exogenous SEMA3F or the inhibition of netrin-1 signaling would be promising for cancer therapy.](fphys-09-01662-g003){#F3}

As described above, systemic treatment with SEMA3F (full-length or its mutants) is a potential regulator of the tumor microenvironment; however, further studies on the safety and stability of SEMA3F *in vivo* are required for clinical use. On the other hand, regulation of netrin-1 seems to be more complex because it has multiple promotive and suppressive receptors. Therefore, selective inhibition of the interaction of netrin-1 and key receptor(s) involved in tumor progression is essential. To reduce adverse side effects, further studies on the development of inhibitors, such as small molecule compounds or antibodies, to interfere with netrin-1 and its specific receptor are needed.

Axon guidance molecules may regulate the epithelial mesenchymal transition (EMT), playing a critical role in tumor progression, invasion, and metastasis. For example, treatment with sunitinib induces primary tumor shrinkage and inhibits angiogenesis in a mouse model of pancreatic neuroendocrine cancer (RIP-Tag2). However, it concurrently promotes local invasiveness and distant metastasis, indicating that sunitinib activates the EMT program ([@B40]). Indeed, sunitinib upregulates mesenchymal markers, Snail1, vimentin, and *N*-cadherin in tumors, whereas it inhibits the epithelial marker, *E*-cadherin. Surprisingly, SEMA3A reversed the effects of sunitinib, inhibiting Snail1 and vimentin and inducing *E*-cadherin expression. Further studies are required to understand whether SEMA3F and netrin-1 are involved in the regulation of EMT, especially in the tumor microenvironment.

Inflammation in the tumor microenvironment also affects tumor development and progression as well as the response to therapy ([@B10]; [@B26]). A key mechanism driving inflammation in immune cells is induced by the inflammasome, a cytoplasmic multimeric protein complex that mediates activation of caspase-1, which subsequently promotes the secretion of pro-inflammatory cytokines. Among inflammasome complexes, the Nod-like receptor family member NLRP3 is well characterized and contributes to various diseases such as colorectal cancer and melanoma. It has been reported that NLRP3 mediates IL18 secretion to protect individuals from colitis-associated colorectal cancer ([@B3]; [@B81]). It is possible that axon guidance molecules, such as netrin-1, could contribute in the regulation of inflammasomes, because netrin-1 regulates the mobility of immune cells in association with acute/chronic inflammation in pathological conditions.

Finally, we need to understand the function of axon guidance molecules in the maintenance of cancer stem cells (or tumor-initiating cells). Currently, it is not known whether axon guidance molecules modulate cancer stem cell behavior. Given that cancer stem cells play a pivotal role in drug resistance, future studies will provide new approaches to overcome chemotherapy resistance by targeting axon guidance molecules.

Summary
=======

SEMA3F Is a Powerful mTOR Inhibitor *in vitro* and *in vivo*
------------------------------------------------------------

The SEMA3F-NRP2-Plexin A1 interactions inhibit intracellular PI-3K activity, mTORC2-dependent signaling, RhoA activity, and cytoskeletal stress fiber formation. These inhibitory effects are observed in diverse human cell types, suggesting that SEMA3F has broad therapeutic implications.

Novel Netrin-1 Mechanisms Include Activation of RhoA, CatB, and CREB
--------------------------------------------------------------------

Netrin-1 promotes glioblastoma and medulloblastoma cell invasion in a RhoA-dependent manner. CatB activation is crucial for enhancing tumor cell invasiveness and angiogenesis. Targeting mediators such as netrin-1 and CatB could be candidates for brain cancer therapy.

Axon Guidance Molecules as Biomarker of Tumor
---------------------------------------------

Netrin-1 is a candidate biomarker capable of detecting the invasive, disseminated phenotype in patients with medulloblastoma and predicting their disease status. On the other hand, the expression of SEMA3F is downregulated in highly metastatic tumor cells. Therefore, a balance of netrin-1 and SEMA3F in tumor cells might be a diagnostic and prognostic biomarker for a high metastatic tumor.

Axon Guidance Molecules Modulate Tumor Microenvironment
-------------------------------------------------------

SEMA3F and netrin-1 have multifaceted effects on tumor and surrounding non-tumor cells, including ECs, leukocytes, macrophages, and fibroblasts. We propose that targeting SEMA3F and netrin-1 may be a promising strategy for cancer therapy.
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